# MK0928 Study in Adult Patients With Primary Insomnia (0928-040)(COMPLETED)

> **NCT00266344** · PHASE2 · COMPLETED · sponsor: **H. Lundbeck A/S** · enrollment: 520 (—)

## Conditions studied

- Primary Insomnia

## Interventions

- **DRUG:** MK0928, gaboxadol / Duration of Treatment 3 Weeks
- **DRUG:** Placebo / Duration of Treatment 3 Weeks

## Key facts

- **NCT ID:** NCT00266344
- **Lead sponsor:** H. Lundbeck A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** —
- **Final completion:** 2006-10
- **Target enrollment:** 520 (—)
- **Last updated:** 2015-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00266344

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00266344, "MK0928 Study in Adult Patients With Primary Insomnia (0928-040)(COMPLETED)". Retrieved via AI Analytics 2026-07-31 from https://api.ai-analytics.org/clinical/NCT00266344. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*